{"id":992364,"date":"2026-08-07T16:33:21","date_gmt":"2026-08-07T20:33:21","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-announce-top-line-results-from-the-phase-2-trial-of-abcl635-for-the-treatment-of-moderate-to-severe-vms-due-to-menopause-on-monday-august-10-2026\/"},"modified":"2026-08-07T16:33:21","modified_gmt":"2026-08-07T20:33:21","slug":"abcellera-to-announce-top-line-results-from-the-phase-2-trial-of-abcl635-for-the-treatment-of-moderate-to-severe-vms-due-to-menopause-on-monday-august-10-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-announce-top-line-results-from-the-phase-2-trial-of-abcl635-for-the-treatment-of-moderate-to-severe-vms-due-to-menopause-on-monday-august-10-2026\/","title":{"rendered":"AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026"},"content":{"rendered":"

<\/p>\n

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026<\/b><\/p>\n

Management to host a conference call and live webcast at 4:30 a.m. PT \/ 7:30 a.m. ET<\/i><\/p>\n

VANCOUVER, British Columbia–(BUSINESS WIRE<\/a>)–AbCellera<\/a> (Nasdaq: ABCL) will release top-line data from its Phase 2 trial evaluating ABCL635 for the treatment of moderate-to-severe vasomotor symptoms (VMS) due to menopause before the market opens on Monday, August 10, 2026<\/b> and hold an investor conference call at 4:30 a.m. Pacific Time (7:30 a.m. Eastern Time) the same day.<\/p>\n

\nA live audio webcast of the investor conference may be accessed through a link that will be posted on AbCellera\u2019s Investor Relations website<\/a>. A replay will be available through the same link following the conference call.<\/p>\n

About ABCL635<\/b><\/p>\n

\nABCL635 is a potential first-in-class antibody drug for the non-hormonal treatment of moderate-to-severe VMS, commonly known as hot flashes, due to menopause. ABCL635 specifically targets NK3R, a clinically validated G protein-coupled receptor (GPCR) expressed on KNDy neurons in the infundibular nucleus of the hypothalamus. ABCL635 is the first program from AbCellera\u2019s GPCR and ion channel platform to advance into the pipeline, entering the clinic in July 2025. Additional details are available at www.abcellera.com\/pipeline<\/a>.<\/p>\n

\nThe Phase 2 trial of ABCL635 (NCT07118891) is a multicenter, randomized, double-blind, placebo-controlled trial with approximately 80 postmenopausal women designed to evaluate the efficacy of ABCL635 in reducing the frequency and severity of moderate-to-severe VMS.<\/p>\n

About AbCellera Biologics Inc.<\/b><\/p>\n

AbCellera<\/a> (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women\u2019s health, immunology, oncology, and more. For more information, please visit www.abcellera.com<\/a>.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260807393777\/en\/<\/a><\/span><\/p>\n

Inquiries
\n<\/b><\/p>\n

Media: Tiffany Chiu; media@abcellera.com<\/a>, +1(236)521-6774
\n
Investor Relations: Peter Ahn; ir@abcellera.com<\/a>, +1(778)729-9116<\/p>\n

KEYWORDS:<\/b> United States North America Canada<\/p>\n

INDUSTRY KEYWORDS:<\/b> Oncology Health Consumer Women Clinical Trials Pharmaceutical Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026 Management to host a conference call and live webcast at 4:30 a.m. PT \/ 7:30 a.m. ET VANCOUVER, British Columbia–(BUSINESS WIRE)–AbCellera (Nasdaq: ABCL) will release top-line data from its Phase 2 trial evaluating ABCL635 for the treatment of moderate-to-severe vasomotor symptoms (VMS) due to menopause before the market opens on Monday, August 10, 2026 and hold an investor conference call at 4:30 a.m. Pacific Time (7:30 a.m. Eastern Time) the same day. A live audio webcast of the investor conference may be accessed through a link that will be posted on AbCellera\u2019s Investor Relations … <\/p>\n

Continue reading “AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-992364","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-announce-top-line-results-from-the-phase-2-trial-of-abcl635-for-the-treatment-of-moderate-to-severe-vms-due-to-menopause-on-monday-august-10-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026 Management to host a conference call and live webcast at 4:30 a.m. PT \/ 7:30 a.m. ET VANCOUVER, British Columbia–(BUSINESS WIRE)–AbCellera (Nasdaq: ABCL) will release top-line data from its Phase 2 trial evaluating ABCL635 for the treatment of moderate-to-severe vasomotor symptoms (VMS) due to menopause before the market opens on Monday, August 10, 2026 and hold an investor conference call at 4:30 a.m. Pacific Time (7:30 a.m. Eastern Time) the same day. A live audio webcast of the investor conference may be accessed through a link that will be posted on AbCellera\u2019s Investor Relations … Continue reading "AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-announce-top-line-results-from-the-phase-2-trial-of-abcl635-for-the-treatment-of-moderate-to-severe-vms-due-to-menopause-on-monday-august-10-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-07T20:33:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260807393777r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-to-announce-top-line-results-from-the-phase-2-trial-of-abcl635-for-the-treatment-of-moderate-to-severe-vms-due-to-menopause-on-monday-august-10-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-to-announce-top-line-results-from-the-phase-2-trial-of-abcl635-for-the-treatment-of-moderate-to-severe-vms-due-to-menopause-on-monday-august-10-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026\",\"datePublished\":\"2026-08-07T20:33:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-to-announce-top-line-results-from-the-phase-2-trial-of-abcl635-for-the-treatment-of-moderate-to-severe-vms-due-to-menopause-on-monday-august-10-2026\\\/\"},\"wordCount\":352,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-to-announce-top-line-results-from-the-phase-2-trial-of-abcl635-for-the-treatment-of-moderate-to-severe-vms-due-to-menopause-on-monday-august-10-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260807393777r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-to-announce-top-line-results-from-the-phase-2-trial-of-abcl635-for-the-treatment-of-moderate-to-severe-vms-due-to-menopause-on-monday-august-10-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-to-announce-top-line-results-from-the-phase-2-trial-of-abcl635-for-the-treatment-of-moderate-to-severe-vms-due-to-menopause-on-monday-august-10-2026\\\/\",\"name\":\"AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-to-announce-top-line-results-from-the-phase-2-trial-of-abcl635-for-the-treatment-of-moderate-to-severe-vms-due-to-menopause-on-monday-august-10-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-to-announce-top-line-results-from-the-phase-2-trial-of-abcl635-for-the-treatment-of-moderate-to-severe-vms-due-to-menopause-on-monday-august-10-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260807393777r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-08-07T20:33:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-to-announce-top-line-results-from-the-phase-2-trial-of-abcl635-for-the-treatment-of-moderate-to-severe-vms-due-to-menopause-on-monday-august-10-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-to-announce-top-line-results-from-the-phase-2-trial-of-abcl635-for-the-treatment-of-moderate-to-severe-vms-due-to-menopause-on-monday-august-10-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-to-announce-top-line-results-from-the-phase-2-trial-of-abcl635-for-the-treatment-of-moderate-to-severe-vms-due-to-menopause-on-monday-august-10-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260807393777r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260807393777r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-to-announce-top-line-results-from-the-phase-2-trial-of-abcl635-for-the-treatment-of-moderate-to-severe-vms-due-to-menopause-on-monday-august-10-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-announce-top-line-results-from-the-phase-2-trial-of-abcl635-for-the-treatment-of-moderate-to-severe-vms-due-to-menopause-on-monday-august-10-2026\/","og_locale":"en_US","og_type":"article","og_title":"AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026 - Market Newsdesk","og_description":"AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026 Management to host a conference call and live webcast at 4:30 a.m. PT \/ 7:30 a.m. ET VANCOUVER, British Columbia–(BUSINESS WIRE)–AbCellera (Nasdaq: ABCL) will release top-line data from its Phase 2 trial evaluating ABCL635 for the treatment of moderate-to-severe vasomotor symptoms (VMS) due to menopause before the market opens on Monday, August 10, 2026 and hold an investor conference call at 4:30 a.m. Pacific Time (7:30 a.m. Eastern Time) the same day. A live audio webcast of the investor conference may be accessed through a link that will be posted on AbCellera\u2019s Investor Relations … Continue reading \"AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-announce-top-line-results-from-the-phase-2-trial-of-abcl635-for-the-treatment-of-moderate-to-severe-vms-due-to-menopause-on-monday-august-10-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-07T20:33:21+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260807393777r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-announce-top-line-results-from-the-phase-2-trial-of-abcl635-for-the-treatment-of-moderate-to-severe-vms-due-to-menopause-on-monday-august-10-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-announce-top-line-results-from-the-phase-2-trial-of-abcl635-for-the-treatment-of-moderate-to-severe-vms-due-to-menopause-on-monday-august-10-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026","datePublished":"2026-08-07T20:33:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-announce-top-line-results-from-the-phase-2-trial-of-abcl635-for-the-treatment-of-moderate-to-severe-vms-due-to-menopause-on-monday-august-10-2026\/"},"wordCount":352,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-announce-top-line-results-from-the-phase-2-trial-of-abcl635-for-the-treatment-of-moderate-to-severe-vms-due-to-menopause-on-monday-august-10-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260807393777r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-announce-top-line-results-from-the-phase-2-trial-of-abcl635-for-the-treatment-of-moderate-to-severe-vms-due-to-menopause-on-monday-august-10-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-announce-top-line-results-from-the-phase-2-trial-of-abcl635-for-the-treatment-of-moderate-to-severe-vms-due-to-menopause-on-monday-august-10-2026\/","name":"AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-announce-top-line-results-from-the-phase-2-trial-of-abcl635-for-the-treatment-of-moderate-to-severe-vms-due-to-menopause-on-monday-august-10-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-announce-top-line-results-from-the-phase-2-trial-of-abcl635-for-the-treatment-of-moderate-to-severe-vms-due-to-menopause-on-monday-august-10-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260807393777r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-08-07T20:33:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-announce-top-line-results-from-the-phase-2-trial-of-abcl635-for-the-treatment-of-moderate-to-severe-vms-due-to-menopause-on-monday-august-10-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-announce-top-line-results-from-the-phase-2-trial-of-abcl635-for-the-treatment-of-moderate-to-severe-vms-due-to-menopause-on-monday-august-10-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-announce-top-line-results-from-the-phase-2-trial-of-abcl635-for-the-treatment-of-moderate-to-severe-vms-due-to-menopause-on-monday-august-10-2026\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260807393777r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260807393777r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-announce-top-line-results-from-the-phase-2-trial-of-abcl635-for-the-treatment-of-moderate-to-severe-vms-due-to-menopause-on-monday-august-10-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/992364","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=992364"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/992364\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=992364"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=992364"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=992364"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}